# A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Agents.

> **NCT00504777** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 36 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** rituximab [MabThera/Rituxan]
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT00504777
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2014-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00504777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00504777, "A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Agents.". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00504777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*